⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for pnets

Every month we try and update this database with for pnets cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine OriginNCT00958841
Pancreatic Neop...
Pituitary Neopl...
Nelson Syndrome
Ectopic ACTH Sy...
pasireotide LAR
18 Years - Novartis
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETsNCT02943733
Neuroendocrine ...
Neoplasms
Cancer
Tumors
TAS-102
Temozolomide
Filgrastim
Pegfilgrastim
18 Years - University of Wisconsin, Madison
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine OriginNCT00958841
Pancreatic Neop...
Pituitary Neopl...
Nelson Syndrome
Ectopic ACTH Sy...
pasireotide LAR
18 Years - Novartis
Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours StudyNCT02358356
Midgut Neuroend...
Pancreatic Neur...
octreotate
Capecitabine
Temozolomide
18 Years - Australasian Gastro-Intestinal Trials Group
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETsNCT02943733
Neuroendocrine ...
Neoplasms
Cancer
Tumors
TAS-102
Temozolomide
Filgrastim
Pegfilgrastim
18 Years - University of Wisconsin, Madison
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: